A U.S. Dept. of Justice probe into Medtronic Inc.’s (NYSE:MDT) marketing practices for its Infuse bone growth product line is growing, according to a report in the New York Times. The Old Grey Lady ...

For the first time, U.S. regulators have cleared Medtronic's controversial Infuse Bone Graft biologic product for lower-back surgery for use with plastic — rather than titanium — spinal components.

DUBLIN and CHICAGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. FDA approval of a prospective, randomized pivotal clinical trial for the use of Infuse™ Bone Graft ...

Two patients who were injured by Medtronic's controversial Infuse bone graft product will receive a combined $8.45 million in settlements with the University of California Los Angeles, where a doctor ...

June 2 (Reuters) - Managed care company Humana Inc has filed a lawsuit against Medtronic Inc accusing the medical device maker of falsely representing its Infuse bone growth-stimulation product as ...

Please provide your email address to receive an email when new articles are posted on . Bone voids, or bone marrow lesions, and other bone defects of the skeletal system are typically non-traumatic, ...

A study comparing the safety and effectiveness of Infuse Bone Graft material to autogenous bone graft when used in maxillary sinus floor augmentation demonstrated that Infuse has similar rates of ...

Medtronic has announced that an independent Data Monitoring Committee (DMC) reviewed the initial interim analysis and confirmed that the randomised controlled trial of INFUSE Bone Graft in the ...